ARCH Venture Partners
VC Fund
Chicago, United States
ARCH Venture Partners is a VC fund in Chicago focused on Biotechnology and Health Care. ARCH invests primarily in companies co-founded by scientists and entrepreneurs, concentrating on bringing to market innovations in life sciences. They enjoy special recognition as a leader in the successful commercialization of technologies developed at academic research institutions and national laboratories.ARCH has raised ten venture fundstotaling over $3 billion and has invested in the venture capital rounds for more than 150 companies. ARCH investors include corporations, pension funds, endowment funds, financial institutions, and private investors.
- Total investments:
- 433
- Last investment:
- Lead investor:
- 31%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries ARCH Venture Partners invests in
Stages ARCH Venture Partners invests in
Countries ARCH Venture Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $10M–$216M
- Series B
- $14M–$250M
- Series C
- $15M–$167M
Investment Focus
Industry
- Biotechnology 166 (38%)
- Health Care 97 (22%)
- Therapeutics 63 (15%)
- Medical 56 (13%)
- Pharmaceutical 43 (10%)
Stage
- Series A 121 (28%)
- Series B 90 (21%)
- Series C 45 (10%)
- Funding Round 33 (8%)
- Series D 19 (4%)
Country
- United States 184 (42%)
- China 12 (3%)
- United Kingdom 4 (1%)
- Canada 2 (0%)
- Ireland 2 (0%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Cindy Bayley
Affiliate
|
Affiliate | Total investments: 0 | Find email | |
Clinton Bybee
Co-Founder and Managing Director
|
Co-Founder and Managing Director | Total investments: 17 | Find email | |
Hong Hou
Venture Partner
|
Venture Partner | Total investments: 0 | Find email | |
Keith Crandell
Co-founder & Managing Director
|
Co-founder & Managing Director | Total investments: 18 | Find email | |
Kristina Burow
Managing Director
|
Managing Director | Total investments: 23 | Find email | |
| See all 16 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
LifeMine Therapeutics
|
Discovering powerful new drugs from eukaryotic microbes by combining Genomics with AI and Synthetic Biology. Founded by Gregory Verdine, PhD, Rick Klausner, MD and WeiQing Zhou, MBA, LifeMine Therapeutics is headquartered in Cambridge, Massachusetts. | $188M / Series E / Aug 06, 2026 | |
Oratomic
|
Oratomic develops neutral-atom quantum hardware and architectures for fault-tolerant quantum computing. The company focuses on utility-scale quantum computers that use light and atoms to implement ultra-efficient quantum error correction. Its work targets applications ranging from scientific discovery to new approaches in artificial intelligenceand complex simulation. Oratomic combines expertise in quantum error correction, neutral-atom platforms, optical engineering, and machine learning. The organization aims to make fully fault-tolerant quantum computing practical for real-world use cases. | $300M / Series A / Jul 07, 2026 | |
Ollin Biosciences
|
Ollin Biosciences operates as a clinical-stage biopharmaceutical company dedicated to acquiring and developing best-in-disease therapies for vision-threatening diseases. | $330M / Series B / Jun 24, 2026 | |
Trase
|
Trase provides and implements complete AI agent solutions, allowing businesses to automate complicated administrative procedures and operations in a safe and secure manner. | $107M / Seed / Jun 24, 2026 | |
City Therapeutics
|
City Therapeutics is a biopharmaceutical company focusing on engineering next-generation small-interfering RNAs (siRNAs) to enhance RNAi-based therapies. The company develops a pipeline of innovative RNAi therapeutics aimed at addressing various disease indications. City Therapeutics prioritizes improving and expanding RNAi technology to achievebetter patient outcomes. The leadership team includes experienced scientists and industry professionals dedicated to advancing the field of RNA interference. | $99.5M / Series B / Jun 08, 2026 | |
|
City Therapeutics
|
City Therapeutics is a biopharmaceutical company focusing on engineering next-generation small-interfering RNAs (siRNAs) to enhance RNAi-based therapies. The company develops a pipeline of innovative RNAi therapeutics aimed at addressing various disease indications. City Therapeutics prioritizes improving and expanding RNAi technology to achievebetter patient outcomes. The leadership team includes experienced scientists and industry professionals dedicated to advancing the field of RNA interference. | $99.5M / Series B / Jun 08, 2026 | |
Countable Labs
|
Countable Labs provides a PCR system for single-molecule counting and high-sensitivity molecular detection in biotechnology. | $26M / Series A / May 28, 2026 | |
CREATE Medicines
|
Myeloid Therapeutics is an immunology company focused on combining immunologic insights with cutting-edge technologies to harness myeloid cells to eradicate cancer and other diseases. The Company's ATAKTM platform technology can be broadly applied, and it is initially advancing a cell therapy program for T cell lymphoma and a primed monocyteapproach to treat glioblastoma. The ATAK platform is scalable to multiple treatment modalities and other disease areas in collaboration with partners. | $122M / Series B / May 14, 2026 | |
Moleculent
|
Moleculent is on a mission to develop technology-enabled products that leverage new insights into the molecular foundation of human biology. Developing amazing products to advance human health gives you purpose. they believe that our understanding of the molecular basis of human biology, in health and disease will increase radically in the comingten years. This will lead to a vast improvement in therapies, diagnostics, and a new, fundamental understanding | $20M / Series A / Apr 30, 2026 | |
Prometheus
|
Project Prometheus develops AI tools designed to learn from and interact with the physical world, rather than just process digital data. Its product efforts target engineering and manufacturing in aerospace, automotive, and computing sectors, using AI to optimize design, production, and performance. | $10B / Venture - Series Unknown / Apr 23, 2026 | |
| See all 433 investments → | |||
Co-Investors
Google Ventures
77 deals together
Alexandria Venture Investments
39 deals together
F-Prime
38 deals together
Polaris Partners
38 deals together
Venrock
38 deals together
Altitude Life Science Ventures
28 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does ARCH Venture Partners invest in?
ARCH Venture Partners invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 433 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is ARCH Venture Partners's check size?
ARCH Venture Partners typically joins rounds of $10M–$216M at Series A, $14M–$250M at Series B and $15M–$167M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds ARCH Venture Partners participates in.
How do I contact ARCH Venture Partners?
Public channels for ARCH Venture Partners include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at ARCH Venture Partners?
The team at ARCH Venture Partners includes Cindy Bayley (Affiliate), Clinton Bybee (Co-Founder and Managing Director) and Hong Hou (Venture Partner), among 16 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
